Penny stock picks | research with support and resistance for trading | stock investing
day investing picks penny stock trading
Skip Navigation Links
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event

Join Now

Advertise 2 my advertising 3 of 5

NEKTAR THERAPEUTICS COM support, resistance research

Stock : NKTR |   Stock Recommendations : Buy
Sector : Medical Equipment & Supplies |   First resistance : 7.26
Stock Name : NEKTAR THERAPEUTICS COM |   Second resistance : 13.15
Buy Near : 5.53 |   Third resistance : 17.00
StopLoss : 3.64 |   First Support : 3.64
Posted date : 11/2/2008 12:00:00 AM |   Second Support : 2.91

Nektar Therapeutics com (NKTR) given a nice double top breakout on 10/31/08 with good volume. Again many technical indicators also have given a buy signal, with

   rising moving average weekly and daily Stockhastic given a buy signal and ADX also given a buy signal. Nektar Therapeutics com (NKTR) reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102. As per technical indicator analysis this Stock looks good candidate for portfolio investment and also for day trading, Stock investing, trend trading | swing trading. Due to Stock market and economic condition keep tight stop loss on all position. Buy with our first target $7.26 and keep stop loss $3.64

Penny Stocks

Recent News Head Lines
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
(Mon, 07 Jun 2021 12:30:00 +0000)
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time.
Should Shareholders Reconsider Nektar Therapeutics' (NASDAQ:NKTR) CEO Compensation Package?
(Fri, 04 Jun 2021 14:46:42 +0000)
Nektar Therapeutics ( NASDAQ:NKTR ) has not performed well recently and CEO Howard Robin will probably need to up their...
We're Interested To See How Nektar Therapeutics (NASDAQ:NKTR) Uses Its Cash Hoard To Grow
(Thu, 27 May 2021 10:36:03 +0000)
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity
(Thu, 20 May 2021 15:00:00 +0000)
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to selectively stimulate T regulatory (Treg) cell function. NKTR-358 is currently in development for the treatment of a range of autoimmune and inflammatory disorders. These published data demonstrate that NKTR-358 has the ability to elicit sustained and preferential proliferation and activation of Tregs in vivo without corresponding increases in T effector cells.
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)
(Tue, 18 May 2021 12:00:00 +0000)
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data from its second major immuno-oncology cytokine program, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC). NKTR-255 is a novel recombinant human Interleukin-15 (rhIL-15) receptor agonist designed to activate the IL-15 pathway to expand both natural killer (NK) cells and memory CD8+ T cell populations. The published data demonstrate that NKTR-255 retains the full spectrum of IL-15 biology but with improved pharmacologic properties and anti-tumor activity versus other rhIL-15 agonists. These preclinical findings support Nektar's robust clinical development program for NKTR-255 in patients with hematologic malignancies and solid tumors.

Never go against major trend for Penny stock trading | investing

Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006
Chart courtesy of
Penny stock trading- NEKTAR THERAPEUTICS COM for penny stock investing Day Trading

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.